🇺🇸 FDA
Patent

US 11708413

Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates

granted A61KA61K2039/505A61K47/6803

Quick answer

US patent 11708413 (Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates) held by Sutro Biopharma, Inc. expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sutro Biopharma, Inc.
Grant date
Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K2039/505, A61K47/6803, A61K47/68031, A61K47/68033